• Type II DM (Victoza):
    • Adults and >10 years: Initially SC 0.6mg OD *1/52, then increase to 1.2mg OD
    • Max 1.8mg/day
  • Cardiovascular event risk reduction in Type II DM with established cardiovascular disease (Victoza):
    • Initially SC 0.6mg OD *1/52, then increase to 1.2mg OD
    • Max 1.8mg/day
  • Long term treatment of obesity in adults with a BMI of ≥30kg/m2 (obese) or ≥27 kg/m2 (overweight) who have at least 1 weight-related condition (e.g. hypertension, type II DM, dyslipidemia) (Saxenda):
    • Adults and >10 years: Initiate at SC 0.6mg OD *1/52
    • Increase by 0.6mg/day in weekly intervals until a dose of 3mg/day achieved
    • Discontinue Saxenda if the patient has not lost at least 4% of baseline body weight for adults and 1% for children

Injection: 6mg/mL

  • Administer SC in abdomen, thigh or upper arm
  • Rotate injection site
  • Must not be administered IV or IM
  • Administered without regard to meals
  • If dose is missed >3 days since the last dose, initiate therapy at 0.6mg/day to avoid GI symptoms

GLP-1 Agonists; Incretin mimetics

It activates glucagon-like-peptide-1 (GLP-1) receptor thereby increasing insulin secretion, decreasing glucagon secretion and consequently delaying gastric emptying. It also activates glucagon-like-peptide-1 (GLP-1) receptor in the brain, regulating appetite and caloric intake

Victoza

  • Hypoglycemia
  • Nausea
  • Diarrhea
  • Headache
  • Nasopharyngitis
  • Vomiting
  • Decreased appetite
  • Dyspepsia
  • URI
  • Constipation
  • Back pain
  • Increased bilirubin
  • Injection site reaction
  • Increased amylase
  • Increased lipase

Saxenda

  • Nausea & vomiting
  • Diarrhea
  • Constipation
  • Hypoglycemia (peds patients)
  • Injection site reaction
  • Headache
  • Gastroenteritis
  • Dizziness
  • Dyspepsia
  • Fever
  • Fatigue
  • Abdominal pain
  • Increased lipase
  • Abdominal distension
  • Eructation
  • Dyslipidemia (peds patients)
  • GERD
  • UTI
  • Flatulence
  • Cough (peds patients)
  • Depression (peds patients)
  • Extremity pain (peds patients)
  • Increased Ck (peds patients)
  • Rash (peds patients)
  • Insomnia
  • Xerostomia
  • Cholelithiasis
  • Asthenia
  • Anxiety
  • Tachycardia
  • Type 1 DM
  • Pregnancy (Saxenda)
  • Suicidal ideation or history (Saxenda)
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Personal or family history of medullary thyroid carcinoma (MTC)

WARNING:

Risk of thyroid C-cell tumors

  • Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
  • Cidofovir

                          Drug Status

Availability Prescription or OTC by Pharmacist
Pregnancy Category X
Breastfeeding Consider alternative
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Victoza 6mg/mL Injection 3mL Novo Nordisk Phillips Therapeutics